Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

AstraZeneca says it had positive meeting with EU over vaccine row

Published 11/04/2021, 15:40
Updated 11/04/2021, 19:40
© Reuters. FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp

By Francesca Landini

MILAN (Reuters) -AstraZeneca had a positive meeting with the European Commission last week, the Anglo-Swedish company said after an Italian newspaper said the group had not replied to an EU letter of complaint over COVID-19 vaccines within a 20-day deadline.

European Union member states and the pharmaceutical company are at odds over the delivery of shots after the group shipped less than indicated to the EU than in the initial agreement.

Italian daily Corriere della Sera said on Sunday AstraZeneca (NASDAQ:AZN) had yet to react to a letter sent by the Commission on March 19 to complain about low-contract supplies of COVID-19 vaccines.

"We can confirm we have responded to the Commission within the required time-frame of the dispute resolution mechanism, and that our team had a very collaborative meeting with the Commission last week," AstraZeneca's Director of Global Media Relations Matthew Kent said in an emailed message.

Earlier on Sunday a spokesman for the European Commission confirmed that Brussels on March 19 had written to AstraZeneca, calling it "a notice for dispute settlement", adding this was a first step to engage in an dialogue to resolve the issue.

"At this stage we are still waiting for the necessary elements ... we remain in contact with AstraZeneca to ensure timely delivery of a sufficient number of doses," the spokesman had told Reuters, without elaborating.

According to the contract signed between EU and the company, which is public, if a dispute arises, one of the parties shall first notify the problem with a letter. Then, after 20 days from the written notice, they "shall meet and attempt to resolve the dispute by good faith negotiations".

Under the contract signed on COVID-19 vaccines, European Union states had expected to receive 120 million doses by the end of March from AstraZeneca, but the company had supplied only 30.12 million doses, Corriere said.

AstraZeneca's spokesman did not comment on the supply data.

With contagion still rising in many European countries and vaccination campaigns hitting hurdles, some governments have shown increasing irritation with the pharmaceuticals group.

"Manifestly, they (AstraZeneca) did not honour their commitments and thus, in a certain way, they were mocking us Europeans," France's European Affairs Minister Clement Beaune said on Sunday, speaking to LCI television news channel.

© Reuters. FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp

Beaune said the EU letter to the Anglo-Swedish group could even lead to a battle in court.

"We sent a formal notice in recent days, it is the beginning of a possible judicial procedure if the company doesn't fix things," he said, adding that putting pressure on the company to accelerate production in Europe appeared to be a better option compared with starting a legal process, which would take time.

Latest comments

Astrazeneca vaccine is problematic. End of.
The Commission should take responsibility for their own poor planning in placing so much dependency on one vaccine. They are threatening damages against a supplier who is not making a profit. The Commissions reputation will be damaged the most if they continue this aggressive and relentless scapegoating campaign. I can't see any big pharma companies rushing to supply the EU at cost after all this.
No good deed goes unpunished.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.